JPMorgan Chase & Co. acquired a new stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 341,025 shares of the company’s stock, valued at approximately $4,764,000. JPMorgan Chase & Co. owned approximately 1.51% of Mersana Therapeutics as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. DekaBank Deutsche Girozentrale purchased a new position in shares of Mersana Therapeutics in the second quarter valued at about $676,000. Victory Capital Management Inc. purchased a new position in shares of Mersana Therapeutics in the second quarter valued at about $754,000. Finally, RHO Capital Partners Inc. purchased a new position in shares of Mersana Therapeutics in the second quarter valued at about $11,428,000. Institutional investors and hedge funds own 74.64% of the company’s stock.

MRSN has been the topic of several research analyst reports. Leerink Swann initiated coverage on Mersana Therapeutics in a research report on Monday, July 24th. They issued an “outperform” rating and a $23.00 price objective on the stock. Cowen and Company initiated coverage on Mersana Therapeutics in a research report on Monday, July 24th. They issued an “outperform” rating on the stock. Wedbush restated an “outperform” rating and issued a $25.00 price objective on shares of Mersana Therapeutics in a research report on Monday, July 24th. Finally, J P Morgan Chase & Co initiated coverage on Mersana Therapeutics in a research report on Monday, July 24th. They issued an “overweight” rating and a $23.00 price objective on the stock.

ILLEGAL ACTIVITY NOTICE: “JPMorgan Chase & Co. Acquires Shares of 341,025 Mersana Therapeutics, Inc. (MRSN)” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/10/07/jpmorgan-chase-co-acquires-shares-of-341025-mersana-therapeutics-inc-mrsn.html.

Mersana Therapeutics, Inc. (MRSN) opened at 18.925 on Friday. The stock’s market capitalization is $429.84 million. The stock has a 50 day moving average price of $17.40 and a 200 day moving average price of $15.95. Mersana Therapeutics, Inc. has a 12 month low of $12.71 and a 12 month high of $21.01.

Mersana Therapeutics (NASDAQ:MRSN) last posted its earnings results on Friday, August 11th. The company reported ($6.33) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.56) by ($5.77). The firm had revenue of $3.73 million during the quarter, compared to analysts’ expectations of $3.33 million. Equities analysts predict that Mersana Therapeutics, Inc. will post ($6.59) EPS for the current fiscal year.

About Mersana Therapeutics

Mersana Therapeutics, Inc is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug’s chances of attacking cancers.

Want to see what other hedge funds are holding MRSN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mersana Therapeutics, Inc. (NASDAQ:MRSN).

Institutional Ownership by Quarter for Mersana Therapeutics (NASDAQ:MRSN)

Receive News & Stock Ratings for Mersana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics Inc. and related stocks with our FREE daily email newsletter.